Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review. - Wikidata - wikimedia - TriplyDB

Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review.

Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review.

http://www.wikidata.org/entity/Q38073201

about

How to manage aspergillosis in non-neutropenic intensive care unit patients Antibiotic therapy of pneumonia in the obese patient: dosing and delivery CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review.Dosing of antifungal agents in obese people.Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Reply to Simon and to Eljaaly and Nix.Voriconazole treatment in adults and children with hematological diseases: can it be used without measurement of plasma concentration?Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.Population Pharmacokinetics of Voriconazole and CYP2C19 Polymorphisms for Optimizing Dosing Regimens in Renal Transplant Recipients.Voriconazole Dosing in Obese Patients

P2860

Q26999448-EF9B57B9-8B1E-4C80-8493-3B8F46597239 Q29248400-072DA945-C9EC-4FDB-815E-3194603E9589 Q33849298-E67C847D-B328-46FE-8C2D-D9F9714DC81D Q36247129-67D9801A-A197-44C0-A5D8-E355A5E823F0 Q36608562-A5ED06B7-1276-4F64-BA15-6E7C16C730F7 Q38247400-4B614D74-E976-4F1A-B51F-9CAFB43AFC86 Q38660761-C8A2CBFD-5A73-4C22-A6E4-126F273D4A84 Q38880522-913F67E4-4781-4162-9473-14E1A4EE11F2 Q48057161-608ADCDC-DC68-45D2-81EC-210B809975EB Q49385523-56AD12EB-DC3E-4AEC-97BB-6EF05A045C50 Q51110220-6C72EE6C-F4C0-47F9-A83D-D5ECB255D4E4 Q52614215-3B65AE92-D490-4E6A-A500-AA0D279D7FBF Q58417081-76198E8B-5AF3-43D9-B4CC-201151F92DB4

P2860

Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review.

http://www.wikidata.org/entity/Q38073201

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Voriconazole serum concentrati ...... ients: a retrospective review.

@en

type

label

Voriconazole serum concentrati ...... ients: a retrospective review.

@en

prefLabel

Voriconazole serum concentrati ...... ients: a retrospective review.

@en

P1433

Q38073201-5C88D849-0344-4F99-BAE8-28DA3C4405A2

P1476

Q38073201-FC2B21F3-4517-4ECB-832C-31F694852732

P2093

Q38073201-2F14C2FF-37CA-4473-9CE2-C0E34CD1E419

Q38073201-7F71F06D-99C9-4C28-8B05-F5F83F4D4DF8

Q38073201-88CB0714-753C-4C37-B666-D0499DE4B94C

Q38073201-9A4CEA9E-DD14-4684-A28D-E2D6A6CA2D58

Q38073201-C3A7FE50-2405-4093-A889-C3A6E067C5E5

P2860

Q38073201-001CD2BA-6530-4CCE-A755-931A9DBBA93A

Q38073201-04747648-B137-4A60-B458-B800991A8C4B

Q38073201-0534C7CC-C29D-45FB-867F-6B919A67CD66

Q38073201-09586765-8202-4A7C-BB4A-1A8175F743B4

Q38073201-1208CEC6-11BB-4CD2-9FA4-61A99A23E40D

Q38073201-1D8C37CF-44AF-4849-83EB-D21FE4DFD4A0

Q38073201-2183682C-D87E-43CC-9162-FFB7A991FD51

Q38073201-274F10F5-418C-4751-9C9D-75F0ABF51B33

Q38073201-2948E220-E732-4366-BC4E-1390FE5255D9

Q38073201-2B99D404-AB61-4694-9868-06F7AFAC1425

P304

Q38073201-0F183953-DFC9-44D9-8AB4-E3E356A5C5C9

P31

Q38073201-655F7E94-EFE2-45F3-B4E3-5EDF6ABE0163

P356

Q38073201-B5E7963A-4FE4-406F-A82B-EB653A1324BC

P407

Q38073201-72D67449-6297-49BE-B3E5-46B9C6B0F7D1

P433

Q38073201-F4C350B3-070F-43C0-B4A9-FCA5FF945170

P478

Q38073201-707D376A-5238-42BB-812E-CFF384779288

P577

Q38073201-405A2C04-7BB4-40FB-97C2-5ADA212204FE

P698

Q38073201-CE391A59-0FD1-4000-BCDE-D3E48CB85D31

P921

Q38073201-4CD2F81C-F121-4AF6-8D7D-5F4E2938FEEB

P356

P1433

Pharmacotherapy

P1476

Voriconazole serum concentrati ...... ients: a retrospective review.

@en

P2093

Bernard R Tegtmeier

http://www.w3.org/2001/XMLSchema#string

James I Ito

http://www.w3.org/2001/XMLSchema#string

Jane Kriengkauykiat

http://www.w3.org/2001/XMLSchema#string

Samantha Davies-Vorbrodt

http://www.w3.org/2001/XMLSchema#string

Sanjeet S Dadwal

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole therapeutic drug monitoring.

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Prevalence and trends in obesity among US adults, 1999-2008

Aspergillosis case-fatality rate: systematic review of the literature.

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

P304

22-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1156

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23307541

http://www.w3.org/2001/XMLSchema#string

P921